Lessons in diversifying, deal-making and remaining independent, with Sinclair Pharma's Alan Olby

25 June 2016

UK-based Sinclair Pharma (LSE: SPH) has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months.

With some of its previously-held dermatology products in steady decline, opportunities arising in aesthetics and the possibility of selling the company to consider, it has come out of this period of uncertainty and now appears to have a very bright future ahead.

Its careful strategizing, divestments and deal-making with bigger players in creating this bright future provide something of a model on how specialty pharma companies can diversify and rid themselves of costly, cumbersome assets and develop a new, more streamlined focus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK